PARP1 and ovarian carcinoma: Currently, HR-related mutation signatures including the recently published Signature 3, a few gene expression profiles applicable to breast and ovarian cancers, and a small number of HR assays are available for prediction of susceptibility to PARP inhibitors [41–45].